



Article

Prostate Apoptotic Induction and NF κ B Suppression by Dammarolic Acid: Mechanistic Insight into Onco-Therapeutic Action of an Aglycone Asiaticoside

Ahmed Alafnan ¹, Talib Hussain ^{1,*}, Syed Mohd Danish Rizvi ^{2,*}, Afrasim Moin ² and Abdulwahab Alamri ¹

¹ Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail P.O. Box 2240, Saudi Arabia; a.alafnan@uoh.edu.sa (A.A.); a.alamry@uoh.edu.sa (A.A.)

² Department of Pharmaceutics, College of Pharmacy, University of Hail, Hail P.O. Box 2240, Saudi Arabia; a.moinuddin@uoh.edu.sa

* Correspondence: mdth_ah@yahoo.com (T.H.); sm.danish@uoh.edu.sa (S.M.D.R.)

Abstract: Prostate cancer (PCa) is addressed as the second most common form of onco-threat worldwide and is usually considered as the major cause of mortality in men. Recent times have seen a surge in exploration of plant-derived components for alternative therapeutical interventions against different oncological malignancies. Dammarolic acid or Asiatic acid (AsA) is an aglycone asiaticoside that has been reported for its efficacy in several ailments including cancer. The current study aimed to investigate the anti-proliferative potency of AsA against human prostate cancer PC-3 cells. Purified AsA was diluted and PC-3 cells were exposed to 20, 40, and 80 μ M concentration and incubated for 24 h. Post-exposure, PC-3 cells showcased a substantial loss of their viability at 20 μ M ($p < 0.05$), moreover, this reduction in cell viability escalated proportionally with an increase in AsA at concentrations of 40 and 80 μ M ($p < 0.01$; $p < 0.001$) respectively. AsA-impelled loss of cellular viability was also evident from the acridine orange-stained photomicrographs, which was also used to quantify the viable and apoptotic cells using Image J software. Additionally, quantification of ROS within PC-3 cells also exhibited an increase in DCF-DA-mediated fluorescence intensity post-exposure to AsA in a dose-dependent manner. AsA-induced apoptosis in PC-3 cells was shown to be associated with augmented activity of caspase-3 proportionally to the AsA concentrations. Thus, initially, this exploratory study explicated that AsA treatment leads to anti-proliferative effects in PC-3 cells by enhancing oxidative stress and inciting apoptosis en route to onset of nuclear fragmentation.



Citation: Alafnan, A.; Hussain, T.; Rizvi, S.M.D.; Moin, A.; Alamri, A. Prostate Apoptotic Induction and NF κ B Suppression by Dammarolic Acid: Mechanistic Insight into Onco-Therapeutic Action of an Aglycone Asiaticoside. *Curr. Issues Mol. Biol.* **2021**, *43*, 932–940. <https://doi.org/10.3390/cimb43020066>

Academic Editor: Raffaele Capasso

Received: 24 July 2021

Accepted: 4 August 2021

Published: 10 August 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: prostate cancer; PC-3 cell; Asiatic acid; apoptosis; anti-proliferative

1. Introduction

Prostate cancer or PCa represent a common malignant tumor occurring within the genitourinary system in males and was accountable for 1,414,259 or 7.3% of new cancer-related cases during 2020 [1]. PCa is also known to be the foremost reason behind cancer-related mortalities among males globally. It has been reported that males having African ancestry are correlated with higher chances of developing the disease more aggressively than other ethnic groups, making them vulnerable to high mortality rates [2,3]. Furthermore, the highest amount of new PCa cases, accounting for 33.5%, were recorded alone in Europe followed by Asia (26.2%). Caribbean accounts for the highest amount of cancer-related deaths after the USA [1]. This debilitating oncological malignancy is associated with a number of varying risk factors among which the prominent ones include apoptosis modulation, genetically and epigenetically governed factors involved in the onset, proliferation, and metastasis [4].

Standard therapeutical management of prostate-related oncological malignancies relies upon surgical, chemo/radio-therapeutics, and hormonal or immunotherapeutical interventions. However, these interventions exert their effects synergistically where the

surgical removal of tumor growth is followed by either radio or chemotherapy or a combination of both. Chemotherapeutics involved in management of these malignancies are documented for their cytotoxic effects en route to instigation of apoptosis and are also known to cause arrest of tumor cells in different phases of cell cycle. The current treatment regime for hormone refractory PCa (HRPC) is docetaxel (DTX), which exerts its effect by destabilizing the microtubules homeostasis within the cells [5]. However, prolonged medication with docetaxel is reported to induce drug-specific resistance within individuals suffering from PCa, resulting primarily from mutations within microtubules with concomitant pump-mediated efflux of drug [6,7].

Nevertheless, the chemotherapeutic-based management of prostate cancer patients is also followed by destructive side-effects, which commonly have catastrophic effects on bone-marrow-derived blood cells, hair follicles, and cells within the oral cavity and digestive tract [7].

In overcoming these debilitating effects, herbal medicines constituted by phytoactive constituents are postulated to be indispensable and also supposed to cause substantial reduction in cost associated with chemotherapeutics [8]. Herbal medicines represent approximately 60% of all the chemotherapeutics that are currently being explored in developing novel anti-cancer drugs [9,10]. One such important bioactive compound is Asiatic acid, which belongs to the family of triterpenoids that have received serious consideration over the past several years. Dammarolic acid or Asiatic acid (AsA) represents pentacyclic triterpenoids, substituted by ursane at 28 positions, and -OH group at 2, 3, and 23 positions. AsA is a major constituent of *Centella asiatica*, *Purnella vulgaris*, *Nepeta hindostana*, *Eucalyptus perriniana*, and *Psidium guajava*. [11]. Earlier it was elucidated that AsA possess intrinsic characteristics that allow it to exert opposing effects on inflammation, diabetes, and cancer [12]. Anti-cancer efficacy of AsA was earlier reported in vitro in both the hepatic and breast cancer cells and was recently deduced to be linked with instigation of apoptosis. Moreover, AsA is further believed to negatively regulate the expression level of NF- κ B, p38, MAPK, and ERKs, along with Bcl-2 and caspase proteins [13,14].

NF- κ B is an important transcription factor playing prominent roles during inflammation and carcinogenesis and, therefore, is regarded as a plausible novel target for therapeutic intervention against cancer [15–17]. Chronic activation of NF- κ B in cancer assists in the onset; progression of tumor; metastasis; and resistance towards chemotherapeutics by augmenting the expression of various growth factors, pro-inflammatory cytokines, chemokines, and anti-apoptotic factors [17–20]. To the best of our knowledge, there appears to be a paucity of scientific literature exploring the potency of AsA in modulating NF- κ B expression within human prostate cancer PC-3 cells. Therefore, this preliminary investigation tries to revisit the anti-proliferative characteristics of AsA on PC-3 cells. It was hypothesized during this investigation that exposure of PC-3 cells with AsA would play a substantial role in restraining the proliferation of human-derived androgen-independent PC-3 cells by escalating ROS, which would further instigate apoptosis via modulation of caspase activity and NF- κ B expression.

2. Materials and Methods

2.1. Materials

Asiatic acid (AsA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), *N*-Acetyl cysteine (NAC), 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA), Acridine orange, ethidium bromide (EtBr) solution, Trypan blue, and caspase-3 inhibitors (Z-DEVD-FMK) were obtained from Sigma, St. Louis, MO, USA. Roswell Park Memorial Institute (RPMI 1640) and antibiotic-antimycotic solution were purchased from Himedia, Pune, India, whereas fetal bovine serum (FBS) used during in vitro culture was obtained from Gibco, West Chester, PA, USA. All the real-time primers employed in the study were synthesized and procured from Integrated DNA Technologies (IDT), Coralville, IA, USA. Verso cDNA synthesis kit and DyNAmoColorFlash SYBR Green qPCR Kit were obtained from Thermo-Scientific, Waltham, MA, USA.

2.2. Methods

2.2.1. Cell Culture and Its Maintenance

Androgen-independent human prostate cancer PC-3 cells were obtained from the cell repository of National Centre for Cell Sciences (NCCS), Pune, India. The PC-3 cells were maintained in Roswell Park Memorial Institute (RPMI 1640) during the entire course of experimentation. The mediums were also supplemented with 10% FBS (*v/v*) and 1% antibiotic-antimycotic solution (*v/v*). Cells were incubated under optimum cell culture conditions constituted by 5% CO₂ at 37 °C. Cells were routinely observed and passaged after attaining ~90% confluency within T-25 flask. Cells were used in pre-determined numbers in accordance with the assay after ascertaining the count of live cells through 0.4% trypan blue dye solution aided by hemocytometer, Sigma, St. Louis, MO, USA.

2.2.2. Assessment of AsA Mediated Toxicity

To explore AsA-induced cytotoxicity (if any) on PC-3 cells, tetrazolium-based MTT assay was undertaken as described previously [21]. PC-3 cells were seeded at a density of 5×10^3 cell/well in a 96-well format and allowed to adhere under optimum culture conditions as stated. After adherence, the cells were exposed to varying concentrations of AsA viz. 20, 40, and 80 µM, and were again subjected to optimum culture conditions for 24 h. Post-incubation, media containing AsA in each well were exchanged with 10 µL of MTT dye (5 mg/mL) and the plate was left for another incubation of 4 h under standard culture conditions. Thereafter, 100 µL of DMSO was included in each well and the plate was vortexed gently at room temperature for nearly 30 min. Finally, the absorbance of solubilized formazan crystals was recorded at 490 nm using a spectrophotometer (Bio-Rad, Hercules, CA, USA). The cytotoxicity of AsA PC-3 cell line was annotated as cell viability percent (%) in comparison with untreated control cells and estimated as $A_{\text{test}} \times 100 / A_{\text{control}}$, where A_{test} = absorbance of treated groups and A_{control} = absorbance of control.

2.2.3. Evaluation of AsA Effects on Alteration of ROS Levels within PC-3 Cells

ROS generation within human prostate cancer PC-3 cells after treatment with AsA was analyzed using quantitative method based on DCFH-DA-mediated fluorescence intensity as described earlier [22]. Initially, 2×10^4 C-3 cells/well were placed in a black bottom 96-well format and left overnight to facilitate their adherence under culture conditions. Post adherence, PC-3 cells were exposed to varying concentrations of AsA (20–80 µM) and were incubated for the next 12 h in optimum culture conditions. Thereafter, media in each well was eliminated and wells were reinstated with 10 µM DCFH-DA followed by another incubation of 30 min in dark. Eventually, the cells were analyzed for their DCF-DA-mediated fluorescence intensity through Synergy H1 Hybrid Reader, BioTek, Winooski, VT, USA fluorescent microplate reader at an excitation/emission wavelength of 485/528 nm. The fluorescent intensity was expressed as average fluorescence percent (%) in comparison with untreated control.

2.2.4. Assessment of AsA Induced Apoptosis Using Acridine Orange (AO) Staining

Initiation of apoptosis within PC-3 cells exposed to AsA was estimated with AO and EtBr double staining. The apoptotic PC-3 cells were visualized using a green filter of Flouid Imaging station as per the adopted protocol with subtle modifications [23]. Briefly, 1×10^5 PC-3 cells were exposed to the above-stated concentrations of AsA in a 6-well plate for 24 h under standard culture conditions. Cells were subsequently detached through gentle scarping and centrifuged (1500 rpm; 2 min at 4 °C), and the pellet was subjected to gentle washing using cold PBS. Thereafter, a 10 µL of AO was used to treat the pellets for 15 min. The suspension was then visualized on a glass slide.

2.2.5. Evaluating Caspase-3 Activity within AsA Exposed PC-3 Cells

Caspase-3 activity was assessed colorimetrically through commercially available kit within AsA-treated human prostate cancer PC-3 cells by adhering to the manufacturer's

instruction. Briefly, 3×10^6 PC-3 cells ensuing AsA treatment at stated concentrations were lysed for 10 min using 50 μ L of ice cold lysis buffer placed on ice. The suspension obtained thereafter was subjected to centrifugation for 1 min at 10,000 rpm and 4 °C after which the supernatant was extracted and placed again on ice. Subsequently, 50 μ L of lysate was placed in each well of a 96-well format and mixed with equi-volume of 10 mM DTT. Finally, 4 mM DEVD-pNA was supplemented further to each well and allowed to react for 10 min at RT. The plate was then assessed for the absorbance of each well at 405 nm through a microplate reader Bio-Rad, Hercules, CA, USA. Alteration within caspase activity was substantiated in percent (%) in correlation with untreated PC-3 control cells.

2.2.6. Assessment of Caspase-3 Inhibitor Mediated Effects on Human Prostate Cancer PC-3 Cells

AsA-induced toxic effects on human prostate cancer PC-3 cells was further delineated through caspase-3 inhibitor Z-DEVD-FMK. Primarily, PC-3 cells were pretreated using Z-DEVD-FMK (50 μ M; 2 h). Subsequently, cells were exposed to AsA (stated concentrations) and left undisturbed for 24 h under standard culture conditions. Eventually, the viability of AsA-treated PC-3 cells was assessed through standard MTT as outlined in Section 2.2.2.

2.3. Statistical Analysis

Experimental data reported here are mean \pm SEM of three discrete experiments performed thrice. Statistical analysis was determined using GraphPad Prism Ver.5.0, San Diego, CA, USA to ascertain significance levels when the value of probability was <0.05 between different groups through student paired t-test, one way-Anova, subsequently followed by Dunnett post-hoc test. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

3. Results

3.1. AsA Reduced the Cell Viability of PC-3 Cells

To investigate the inhibitory effects of AsA on PCa cells, MTT assay was performed. The cells were treated with different concentrations of AsA (0–80 μ M) for 24 h. As shown in Figure 1A, it was found that AsA substantially inhibited the growth of PC-3 cells by $77.96 \pm 2.98\%$ (20 μ M; $p < 0.05$), $58.71 \pm 4.83\%$ (40 μ M; $p < 0.01$), and $26.85 \pm 5.10\%$ (80 μ M; $p < 0.001$) in a dose-dependent manner.

3.2. AsA Instigated Apoptotic Cell Death within PC-3 Cells

To investigate the apoptotic cell death in AsA-treated PC-3 cells, cells were counted to investigate the number of viable cells (VI) and apoptotic cells (AO) by using fluorescence microscope. As observed in phase contrast micrographs in Figure 1B, apoptotic cells emitted diffuse green fluorescence by using AO within the fragmented DNA of AsA-treated PC-3 cells. Moreover, untreated control cells were distinguished by the presence of bright green fluorescence due to the presence of intact nuclei within the cells. At the highest dose (80 μ M) of AsA, nuclear chromatin condensation and blebbing were observed, which are considered to be peculiar attributes of apoptosis. The results showed that AsA induced morphological aberrations in the nucleus following a dose-dependent trend, which ultimately was associated with apoptosis.

Furthermore, apoptotic cell death was quantitatively assessed in AsA-treated PC-3 cells. As shown in Figure 1C, dose-related decrease of viable cells (VI) with diffused green fluorescence was $45.61 \pm 4.97\%$ (20 μ M), $28.92 \pm 4.83\%$ (40 μ M), and $11.56 \pm 5.10\%$ (80 μ M) as compared to control, where the number of VI was 75.31 ± 4.87 . Contrary to this, AO cells increased to $15.69 \pm 0.39\%$ (20 μ M), $19.33 \pm 0.48\%$ (40 μ M), and $33.65 \pm 0.45\%$ (80 μ M) as compared to the control ($8.56 \pm 0.59\%$). Thus, our results signified that AsA significantly induced apoptotic cell death in PC-3 cells.




Figure 1. (A) Cell viability percentage (%) of human androgen-independent PC-3 cells exposed to various concentrations (20, 40, and 80 μM) of AsA; (B) photomicrographs stained with acridine orange, indicating the viable (VI) and apoptotic (AO) PC-3 cells post treatment with AsA (as indicated by the arrows; scale bar = 100 μm); and (C) quantification of both the VI and AO PC-3 cells. Experimental data reported here are mean \pm SEM of three discrete experiments performed thrice. Statistical significance between control and treated groups was analyzed using student paired t-test, one-way Anova, and Dunnett post-hoc test as per the applicability where significance was illustrated when * $p < 0.05$; ** $p < 0.01$; and *** $p < 0.001$.

3.3. AsA Augmented the Levels of ROS in PC-3 Cells

ROS generation was found to be associated with the apoptosis induction in cancer cells [24]. Therefore, it is necessary to determine the level of ROS in PC-3 PCa cells after treatment with various doses (20–80 μM) of AsA for 24 h. As shown in Figure 2A, substantial increase in the intracellular level of ROS was enhanced by $56.71 \pm 3.04\%$ ($p < 0.001$) compared to untreated cells, following treatment with the 20 μM dose of AsA. Indeed, ROS generation was further enhanced to $116.01 \pm 4.18\%$ and $191.75 \pm 4.55\%$ ($p < 0.001$) in PC-3 cells at the concentrations of 40 μM and 80 μM AsA, respectively. These results suggested that the treatment of AsA augments the ROS generation in PCa cells.

3.4. Assessment of Caspase-3 Activity in AsA-Treated PC-3 Cells

To investigate the mechanism underlying AsA-mediated apoptosis in PC-3 cells, we inspected the intracellular caspases-3 activity in AsA-treated PC-3 cells. As observed in Figure 2B, our findings suggested a substantial increase in the caspase-3 activity to $26.72 \pm 3.94\%$, $59.05 \pm 4.51\%$, and $124.18 \pm 4.95\%$ ($p < 0.05$, $p < 0.001$) as compared to control, at the indicated doses of 20, 40, and 80 μM of AsA, respectively. Thus, our results further confirm that the antiproliferative efficacy of AsA was mediated by inducing apoptosis in PC-3 cells.

3.5. Attenuation of AsA-Mediated Apoptosis in PC-3 PCa Cells by Caspase Inhibitors

To characterize whether the caspases are involved in the AsA-mediated cytotoxicity in PCa cells, PC-3 cells were initially treated with 50 mM caspase-3 inhibitor (Z-DEVD-FMK) for 2 h and then subsequently treated with AsA at the indicated doses for 24 h. Further, MTT assay was used to determine the cell viability as described above. Pretreatment with caspase-3 inhibitor substantially decreased the amount of cytotoxicity in PCa cells caused by the treatment of AsA Figure 2C. These findings suggested that the induction of caspase-3 activity played a critical role in AsA-mediated apoptosis.




Figure 2. (A) Quantitative evaluation of AsA-mediated DCF-DA fluorescence intensity (%) within PC-3 cells; (B) AsA-mediated instigation of caspase-3 at varying concentrations of 20, 40, and 80 μM in PC-3 cells; (C) cell viability (%) of PC-3 cells pretreated with caspase-3 inhibitors and (D) percent activity of NF- κ B transcription factor. Experimental data reported here are mean \pm SEM of three discrete experiments performed thrice. Statistical significance between control and treated groups was analyzed using student paired *t*-test, one-way Anova, and Dunnett post-hoc test as per the applicability where significance was illustrated when * $p < 0.05$; ** $p < 0.01$ and *** $p < 0.001$.

3.6. AsA Inhibits the Activation of NF- κ B in PC-3 Cells

The NF- κ B signaling pathway plays a critical role in the survival of cancer cells and is widely known for regulating the expression of Bcl-2 proteins [25]. Thus, we assessed the NF- κ B activity in PC-3 cells to investigate the efficacy of AsA on NF- κ B activity. AsA treatment led to a dose-dependent decrease in NF- κ B activity to $76.53 \pm 3.37\%$, $57.20 \pm 3.78\%$ ($p < 0.01$) and $35.42 \pm 3.37\%$ ($p < 0.001$) as shown in Figure 2D, indicating that AsA mediated the inhibition of NF- κ B in PCa cells.

4. Discussion

Despite the escalation within incidences and mortality rates of PCa, available therapeutic modalities are not substantially effective in prolonging the mean survival time period of patients. Therefore, there is a quest for exploration and development of novel therapeutic agents that could exhibit enhanced therapeutical efficacy with concomitantly reduced side-effects against PCa patients. Occurrence of tumors involves the evasion of apoptosis, resulting in an uncontrolled proliferation of tumor cells. Thus, an efficient cancer therapy may focus towards utilizing the cytotoxic potential of natural compounds in destroying the malignant cells by triggering the apoptotic pathways with least side effects [26]. The results from our investigation revealed that AsA may exert chemopreventive potential against PCa by modulating certain key cell signaling molecule. It was found that the triterpenoids (AsA) exerted substantial anti-proliferative effects on PC-3 cells via inducing caspase-mediated apoptosis along with suppressing the stimulation of proinflammatory transcription factor NF- κ B, which is chiefly involved in tumor survival and proliferation.

Apoptosis or programmed cell death is an extremely controlled process that plays an imperative role in cell death and is also indispensable in several cellular functions from fetal development to adult tissue homeostasis [27]. Available literature clearly outlines that apoptosis results due to multiple biochemical changes in cells, which primarily includes nuclear condensation and fragmentation, alteration in the mitochondrial membrane

potential, and regulation of caspases [28]. In our present investigation, we explored the cytotoxic potential of AsA on androgen-independent PC-3 cell line. The cell viability analysis suggested that AsA significantly suppressed the proliferation of these cells. The results substantiated that the exposure of AsA strongly curtailed the viability of PC-3, where the reduced viability was directly correlated with the concentration of AsA. Since the exposure of AsA exhibited a strong cytotoxic potential on PC-3 cells, we performed AO fluorescent dye staining to explore the cells undergoing apoptosis and formation of apoptotic bodies within the PCa cells. Although AO photomicrographs clearly demonstrated the morphological alterations associated with apoptosis, we also quantified the population of apoptotic cells by using Image J software (Ver. 1.46r). The observations compelled us to conclude that AsA instigated a substantial dose-dependent increase in apoptosis in PCa.

Previously reports have documented that oxidative stress serves to be a crucial impetus for altering mitochondrial membrane potential and apoptosis [29]. We measured the levels of ROS upon AsA treatment on PC-3 cells to inspect the involvement of ROS in the apoptotic pathways. The observations conclusively made it evident that there was a substantial dose-dependent augmentation within intracellular ROS within AsA-treated PC-3 cells. Caspases are considered to be paramount regulators of apoptosis [30]. Caspase-3 being a chief executioner of apoptosis is partially or completely accountable towards proteolytic cleavage of cellular proteins [31]. Therefore, we inspected the caspase activity in AsA-treated PC-3 cells in juxtaposition with the control and observed that AsA induced caspase-3 activation, leading to apoptosis. Further, pretreatment with caspase-3 inhibitor (Z-DEVD-FMK) significantly reduced AsA-induced cytotoxicity in PC-3 cells, implicating that stimulation of caspase-3 post-AsA exposure induced apoptosis.

Convincing evidence suggested that constitutive activation of NF- κ B is a trademark of multiple human carcinomas [16,32]. Earlier researches have elucidated that NF- κ B is constitutively over-expressed in androgen-independent DU145 and PC-3 PCa cells [33]. NF- κ B is a protein complex involved in adjusting DNA transcription and is considered an apoptosis inhibitor [34]. Therefore, suppressing the functionality of NF- κ B can induce apoptosis. During this investigation, we demonstrated that AsA portrayed its relevance in inhibiting the activation NF- κ B in PC-3 cells. In line with these findings, we conclude that the apoptosis induced by AsA on PC-3 cells could plausibly be correlated with suppressed NF- κ B activity. Conclusively, AsA could be a plausible therapeutic modality in the treatment of PCa.

5. Conclusions

On the basis of inferences drawn from this initial investigative study, AsA is competent in inducing apoptosis in PC-3 cells. The evidences presented herewith provide a connective link between anti-proliferation and apoptotic induction, and the cell death in PCa cells was a result of caspase activation. These findings implicated that apoptosis occurs through intrinsic apoptotic signaling pathways with regulation of NF- κ B protein modulation. Thus, our results affirmed the potency of AsA as a chemotherapeutic agent in human PCa cells, and therefore, may be worthy for application in the optimization and development of novel therapeutical-based interventions against PCa. However, subsequent researches are further warranted to elucidate the molecular mechanics involved in efficacy of AsA as an anticancer agent against PCa cells.

Author Contributions: Conceptualization, A.A. (Ahmed Alafnan) and T.H.; methodology, S.M.D.R.; validation, S.M.D.R., A.M. and A.A. (Abdulwahab Alamri); formal analysis, A.A. (Ahmed Alafnan) and T.H.; resources, A.A. (Abdulwahab Alamri); writing—original draft preparation, A.M. and A.A. (Abdulwahab Alamri); writing—review and editing, S.M.D.R.; supervision, A.A. (Ahmed Alafnan) and T.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors acknowledge the support given by University of Hail, KSA.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Factsheet Prostate Cancer, Global Cancer Observatory. December 2020. Available online: <https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf> (accessed on 5 May 2021).
2. Badal, S.; Aiken, W.; Morrison, B.; Valentine, H.; Bryan, S.; Gachii, A.; Ragin, C. Disparities in prostate cancer incidence and mortality rates: Solvable or not? *Prostate* **2020**, *80*, 3–16. [CrossRef] [PubMed]
3. Bhardwaj, A.; Srivastava, S.K.; Khan, M.A.; Prajapati, V.K.; Singh, S.; Carter, J.E.; Singh, A.P. Racial disparities in prostate cancer: A molecular perspective. *Front. Biosci.* **2017**, *22*, 772–782. [CrossRef]
4. Wang, Y.; Romigh, T.; He, X.; Orloff, M.S.; Silverman, R.H.; Heston, W.D.; Eng, C. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. *Hum. Mol. Genet.* **2010**, *19*, 4319–4329. [CrossRef] [PubMed]
5. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N., Jr.; Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N. Engl. J. Med.* **2004**, *351*, 1513–1520. [CrossRef]
6. Mahon, K.L.; Henshall, S.M.; Sutherland, R.L.; Horvath, L.G. Pathways of chemotherapy resistance in castration-resistant prostate cancer. *Endocr. Relat. Cancer* **2011**, *18*, R103–R123. [CrossRef]
7. Domingo-Domenech, J.; Vidal, S.J.; Rodriguez-Bravo, V.; Castillo-Martin, M.; Quinn, S.A.; Rodriguez-Barrueco, R.; Bonal, D.M.; Charytonowicz, E.; Gladoun, N.; de la Iglesia-Vicente, J.; et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. *Cancer Cell* **2012**, *22*, 373–388. [CrossRef] [PubMed]
8. Shukla, Y.; George, J. Combinatorial strategies employing nutraceuticals for cancer development. *Ann. N. Y. Acad. Sci.* **2011**, *1229*, 162–175. [CrossRef]
9. Gupta, S.C.; Kim, J.H.; Prasad, S.; Aggarwal, B.B. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. *Cancer Metastasis Rev.* **2010**, *29*, 405–434. [CrossRef] [PubMed]
10. Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural products as sources of new drugs over the period 1981–2002. *J. Nat. Prod.* **2003**, *66*, 1022–1037. [CrossRef] [PubMed]
11. Nasir, M.N.; Habsah, M.; Zamzuri, I.; Rammes, G.; Hasnan, J.; Abdullah, J. Effects of asiatic acid on passive and active avoidance task in male Sprague-Dawley rats. *J. Ethnopharmacol.* **2011**, *134*, 203–209. [CrossRef] [PubMed]
12. Lee, Y.S.; Jin, D.Q.; Kwon, E.J.; Park, S.H.; Lee, E.S.; Jeong, T.C.; Nam, D.H.; Huh, K.; Kim, J.A. Asiatic acid, a triterpene, induces apoptosis through intracellular Ca²⁺ release and enhanced expression of p53 in HepG2 human hepatoma cells. *Cancer Lett.* **2002**, *186*, 83–91. [CrossRef]
13. Gurfinkel, D.M.; Chow, S.; Hurren, R.; Gronda, M.; Henderson, C.; Berube, C.; Hedley, D.W.; Schimmer, A.D. Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acid. *Apoptosis* **2006**, *11*, 1463–1471. [CrossRef]
14. Thakor, F.K.; Wan, K.W.; Welsby, P.J.; Welsby, G. Pharmacological effects of asiatic acid in glioblastoma cells under hypoxia. *Mol. Cell. Biochem.* **2017**, *430*, 179–190. [CrossRef]
15. Di Donato, J.A.; Mercurio, F.; Karin, M. NF-κB and the link between inflammation and cancer. *Immunol. Rev.* **2012**, *246*, 379–400. [CrossRef]
16. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: From innocent bystander to major culprit. *Nat. Rev. Cancer* **2002**, *2*, 301–310. [CrossRef]
17. Perkins, N.D. The diverse and complex roles of NF-κB subunits in cancer. *Nat. Rev. Cancer* **2012**, *12*, 121–132. [CrossRef] [PubMed]
18. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle. *Cell* **2002**, *109*, S81–S96. [CrossRef]
19. Kanarek, N.; Ben-Neriah, Y. Regulation of NF-κB by ubiquitination and degradation of the IκBs. *Immunol. Rev.* **2012**, *246*, 77–94. [CrossRef]
20. Nakanishi, C.; Toi, M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. *Nat. Rev. Cancer* **2005**, *5*, 297–309. [CrossRef] [PubMed]
21. Ahmad, A.; Tiwari, R.K.; Saeed, M.; Ahmad, I.; Ansari, I.A. Glycyrrhizin Mediates Downregulation of Notch Pathway Resulting in Initiation of Apoptosis and Disruption in the Cell Cycle Progression in Cervical Cancer Cells. *Nutr. Cancer* **2021**, 1–18. [CrossRef] [PubMed]
22. Ahmad, A.; Ansari, I.A. Carvacrol Exhibits Chemopreventive Potential against Cervical Cancer Cells via Caspase-Dependent Apoptosis and Abrogation of Cell Cycle Progression. *Anticancer Agents Med. Chem.* **2020**, *21*, 1–15. [CrossRef] [PubMed]
23. Abbaspour Babaei, M.; Zaman Huri, H.; Kamalidehghan, B.; Yeap, S.K.; Ahmadipour, F. Apoptotic induction and inhibition of NF-κB signaling pathway in human prostatic cancer PC3 cells by natural compound 2,2'-oxybis (4-allyl-1-methoxybenzene), biseugenol B, from *Litsea costalis*: An in vitro study. *Onco Targets Ther.* **2017**, *10*, 277–294. [CrossRef]

24. Powolny, A.A.; Singh, S.V. Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. *Pharm. Res.* **2008**, *25*, 2171–2180. [[CrossRef](#)]
25. Baldwin, A.S. Regulation of cell death and autophagy by IKK and NF- κ B: Critical mechanisms in immune function and cancer. *Immunol. Rev.* **2012**, *246*, 327–345. [[CrossRef](#)]
26. Shi, Y.; Zhang, L.; Liu, X.; Zhou, C.; Zhang, L.; Zhang, S.; Wang, D.; Li, Q.; Qin, S.; Hu, C.; et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial. *Lancet Oncol.* **2013**, *14*, 953–961. [[CrossRef](#)]
27. Li, P.; Tian, W.; Wang, X.; Ma, X. Inhibitory effect of desoxyrhaponticin and rhaponticin, two natural stilbene glycosides from the Tibetan nutritional food *Rheum tanguticum* Maxim. ex Balf., on fatty acid synthase and human breast cancer cells. *Food Funct.* **2014**, *5*, 251–256. [[CrossRef](#)] [[PubMed](#)]
28. Hunter, A.M.; LaCasse, E.C.; Korneluk, R.G. The inhibitors of apoptosis (IAPs) as cancer targets. *Apoptosis* **2007**, *12*, 1543–1568. [[CrossRef](#)] [[PubMed](#)]
29. Sainz, R.M.; Mayo, J.C.; Rodriguez, C.; Tan, D.X.; Lopez-Burillo, S.; Reiter, R.J. Melatonin and cell death: Differential actions on apoptosis in normal and cancer cells. *Cell. Mol. Life Sci.* **2003**, *60*, 1407–1426. [[CrossRef](#)]
30. Li, Z.; Jo, J.; Jia, J.M.; Lo, S.C.; Whitcomb, D.J.; Jiao, S.; Cho, K.; Sheng, M. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. *Cell* **2010**, *141*, 859–871. [[CrossRef](#)]
31. Ansari, I.A.; Ahmad, A.; Imran, M.A.; Saeed, M.; Ahmad, I. Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes. *Anticancer Agents Med. Chem.* **2021**, *21*, 393–405. [[CrossRef](#)]
32. Haefner, B. NF-kappa B: Arresting a major culprit in cancer. *Drug Discov. Today* **2002**, *7*, 653–663. [[CrossRef](#)]
33. Suh, J.; Payvandi, F.; Edelstein, L.C.; Amenta, P.S.; Zong, W.X.; Gélinas, C.; Rabson, A.B. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. *Prostate* **2002**, *52*, 183–200. [[CrossRef](#)]
34. Bernard, D.; Quatannens, B.; Vandenbunder, B.; Abbadie, C. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. *J. Biol. Chem.* **2001**, *276*, 27322–27328. [[CrossRef](#)] [[PubMed](#)]